- Home
- EIIA vs SBFM Comparison
EIIA vs SBFM Comparison
Compare EIIA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIIA
- SBFM
- Stock Information
- Founded
- EIIA N/A
- SBFM 2006
- Country
- EIIA
- SBFM United States
- Employees
- EIIA N/A
- SBFM 52
- Industry
- EIIA
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- EIIA
- SBFM Health Care
- Exchange
- EIIA Nasdaq
- SBFM Nasdaq
- Market Cap
- EIIA N/A
- SBFM 4.9M
- IPO Year
- EIIA N/A
- SBFM N/A
- Fundamental
- Price
- EIIA N/A
- SBFM $1.25
- Analyst Decision
- EIIA
- SBFM Strong Buy
- Analyst Count
- EIIA 0
- SBFM 1
- Target Price
- EIIA N/A
- SBFM $15.00
- AVG Volume (30 Days)
- EIIA N/A
- SBFM 3.7M
- Earning Date
- EIIA N/A
- SBFM 05-19-2025
- Dividend Yield
- EIIA N/A
- SBFM N/A
- EPS Growth
- EIIA N/A
- SBFM N/A
- EPS
- EIIA N/A
- SBFM N/A
- Revenue
- EIIA N/A
- SBFM $34,874,283.00
- Revenue This Year
- EIIA N/A
- SBFM $192.48
- Revenue Next Year
- EIIA N/A
- SBFM N/A
- P/E Ratio
- EIIA N/A
- SBFM N/A
- Revenue Growth
- EIIA N/A
- SBFM 44.75
- 52 Week Low
- EIIA N/A
- SBFM $1.19
- 52 Week High
- EIIA N/A
- SBFM $91.40
- Technical
- Relative Strength Index (RSI)
- EIIA N/A
- SBFM 27.96
- Support Level
- EIIA N/A
- SBFM $1.36
- Resistance Level
- EIIA N/A
- SBFM $1.65
- Average True Range (ATR)
- EIIA 0.00
- SBFM 0.31
- MACD
- EIIA 0.00
- SBFM -0.04
- Stochastic Oscillator
- EIIA 0.00
- SBFM 2.97
About EIIA Eagle Point Institutional Income Fund
Eagle Point Institutional Income Fund is a closed-end investment company. Its investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.